Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Earlie who wrote (76884)	6/10/2002 10:41:22 PM
From: Zeev Hed	Read Replies (5) \| Respond to of 99280

Earlie, I like what VSV is doing in CHF (except their Psoriasis involvement, a death bed for many biotech <g>), but hey their burn rate is going to increase from their current $3.5 MM/quarter to probably $7 MM/Q with that major multicenters study of 1500 patients. At that rate, despite their issuance of stock recently, they will be running out of cash in a little more than a year. I think that the sector is still under very heavy pressure (and VSV made a new low last week) and could very well reach levels of "cash on hand", which frankly, will be under a buck. What make you so sure "salvation" will be with them? If they attempt to apply their technology to psoriasis, like many others have, it may actually bring a stock catastrophe (if recent history is a guide <g>). Zeev